Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer

May 22, 2009 updated by: Eli Lilly and Company

Phase II Study of Pemetrexed Plus Cisplatin in the Treatment of Patients With Extensive Small Cell Lung Cancer

The purpose of this study is to determine if cisplatin and pemetrexed are effective in the treatment of patients with Small Cell Lung Cancer, extended disease.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

5

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Ferrol, Spain, 15405
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • La Coruña, Spain, 15002
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Lugo, Spain, 27004
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Ourense, Spain, 15009
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Santiago de Compostela, Spain, 15706
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Vigo, Spain, 36211
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Histologic or cytologic diagnosis of Small Cell Lung Cancer (SCLC).
  • Functional stage from 0 to 2 of the ECOG functional scale
  • No previous systemic chemotherapy, immunotherapy or biologic therapy for SCLC.
  • Previous bone marrow radiotherapy less than 25% is allowed.
  • There must be at least one measurable lesion that complies with the solid tumor response evaluation criteria.
  • Appropriate organic function.
  • Life expectancy estimated at 12 weeks minimum.
  • Females must be surgically sterile, postmenopausal or follow approved medical contraceptive methods during the treatment period and 6 months afterwards. Males must be surgically sterile or use a contraceptive method during the treatment period and during 6 months after treatment.
  • The patient must be compliant and located close to the trial area for appropriate follow-up.
  • The patient or his/her legal representative must sign an informed consent document.
  • Patients must be at least 18 years of age.

Exclusion Criteria:

  • Having received treatment for the last 30 days with a drug that has not obtained regulatory approval.
  • Having participated in a previous pemetrexed trial.
  • Mixed histologic diagnosis of SCLC and NSCLC.
  • Concurrent illness.
  • Having an active infection.
  • Severe cardiac disease.
  • Having received recently or concurrently a vaccine against yellow fever.
  • Having suffered a previous malignant process other than SCLC.
  • Central nervous system (CNS) metastases require concurrent corticoid therapy. Treated and stable CNS metastases are allowed.
  • Clinically relevant fluid accumulation in the third space.
  • Significant weight loss (greater than or equal to 10%) within 6 weeks prior to trial inclusion.
  • Concurrent administration of any other anti-tumor treatment.
  • Severe renal failure.
  • Unable to discontinue administration of non-steroidal anti-inflammatory (NSAIDS) agents.
  • Inability or unwillingness to take folic acid and vitamin B12 supplements.
  • Inability to take corticoids.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: A
Drug: pemetrexed
500 mg/m2, intravenous (IV), every 21 days x 6 cycles
Other Names:
  • Alimta
  • LY231514
Drug: cisplatin
75 mg/m2, intravenous (IV), every 21 days x 6 cycles

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Response Rate
Time Frame: baseline to measured progressive disease
Trial terminated - results not analyzed
baseline to measured progressive disease

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Survival
Time Frame: baseline to date of death from any cause
Trial terminated - results not analyzed
baseline to date of death from any cause
Progression Free Survival
Time Frame: baseline to measured progressive disease
Trial terminated - results not analyzed
baseline to measured progressive disease
Duration of Response
Time Frame: time of response to progressive disease
Trial terminated - results not analyzed
time of response to progressive disease
Stable Disease Rate
Time Frame: baseline to measured progressive disease
Trial terminated - results not analyzed
baseline to measured progressive disease

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Eli Lilly and Company

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2007

Primary Completion (Actual)

April 1, 2008

Study Completion (Actual)

April 1, 2008

Study Registration Dates

First Submitted

May 16, 2007

First Submitted That Met QC Criteria

May 16, 2007

First Posted (Estimate)

May 21, 2007

Study Record Updates

Last Update Posted (Estimate)

May 29, 2009

Last Update Submitted That Met QC Criteria

May 22, 2009

Last Verified

May 1, 2009

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 11473
  • H3E-XM-S113

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Small Cell Lung Cancer

Clinical Trials on pemetrexed

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe